Alfresa Holdings (2784) Fundamentals 2026 — P/E 10.1x, Revenue Analysis | SniperIQ
Alfresa Holdings (2784) is a JP-listed Healthcare company in Medical - Distribution with a market capitalization of ¥423.6B, trading at ¥2331.00 on the JPX. This SniperIQ fundamentals page covers Alfresa Holdings's valuation (P/E 10.1x, P/B 0.8x), profitability (net margin 1.3%), revenue (¥3.10T in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Alfresa Holdings's market cap?
Alfresa Holdings (2784) has a market capitalization of approximately ¥423.6B, trading at ¥2331.00 on the JPX. Market cap moves with the live share price.
What is Alfresa Holdings's P/E ratio?
Alfresa Holdings's trailing twelve-month P/E ratio is 10.1x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Alfresa Holdings?
Alfresa Holdings runs a net profit margin of 1.3%, a gross margin of 7.0%, and an operating margin of 1.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Alfresa Holdings generate?
Alfresa Holdings reported revenue of ¥3.10T for fiscal year 2026, with net income of ¥41.7B and earnings per share (EPS) of 229.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Alfresa Holdings pay a dividend?
Alfresa Holdings offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Alfresa Holdings financially healthy?
Alfresa Holdings carries a debt-to-equity ratio of 0.07x and a current ratio of 1.24x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Alfresa Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alfresa Holdings (2784) the key facts are: market cap ¥423.6B, P/E 10.1x, revenue ¥3.10T, 52-week range 2055-2685.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Alfresa Holdings's full fundamentals live
Get Alfresa Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.